McKesson Ventures

McKesson Ventures operates as a dedicated platform team that actively bridges portfolio companies into the parent corporation's commercial operations. The team helps startups access McKesson's provider, payor, and pharmacy networks rather than acting as a passive balance-sheet investor. This creates a structural advantage where portfolio companies can scale through existing distribution channels that touch roughly one-third of U.S. cancer patients and a significant share of American medicines, according to the firm's website.

McKesson Ventures is wholly owned and funded by McKesson Corporation, a healthcare distribution and services company with over $400 billion in annual revenue. Tom Rodgers, who founded the unit in 2014, now serves as EVP and Chief Strategy Officer of the parent company and continues to oversee the Ventures program and its investment committee. This direct C-suite linkage ensures strategic alignment between the venture portfolio and McKesson's broader corporate objectives.

Yes. The firm maintains a dual-stage mandate. The Venture group, led by Partners including Michelle Snyder, Carrie Hurwitz Williams, and Jennifer Carter, targets early-stage and startup companies. The Growth Equity group, led by Partner Peter Lafer, focuses on later-stage businesses. The portfolio includes confirmed positions in clinical-trial technology company Saama and value-based primary-care network Aledade, reflecting the range of stages the firm covers.

President Dave Schulte leads the investment team and manages day-to-day operations. The investment committee is overseen by Tom Rodgers, McKesson's EVP and Chief Strategy Officer. Individual Partners manage active portfolios: Schulte's active investments include Aledade, Clinical Ink, Komodo, and Saama, while Michelle Snyder's include CancerIQ, Midi Health, and RxVantage, among others.

The firm organizes its portfolio into two main sectors: Pharma Tech Services and Health-Tech & Tech Enabled Services. Pharma Tech includes companies that provide software, data analytics, and clinical-trial services to pharmaceutical firms — examples include Aetion and Clinical Ink. Health-Tech focuses on care-delivery models and workflow tools, with portfolio companies such as Aledade (value-based primary care) and IVX Health (infusion centers).

The firm operates as a direct investor rather than a fund-of-funds and does not publicly advertise a co-investment club model or syndicate with outside GPs. Its website presents the team as the sole venture and growth equity investor on behalf of McKesson Corporation, suggesting a preference for direct, proprietary investments that can leverage the parent company's operational assets.

The Ventures unit maintains a dedicated Platform and Insights team that evaluates synergies between portfolio companies and McKesson's operating units. Jennifer Carter, Partner & VP Venture Operations, leads efforts to identify and activate commercial connections within McKesson's pharmacy, oncology, and medical-surgical distribution networks — effectively serving as a bridge between early-stage innovation and scaled distribution.